262 related articles for article (PubMed ID: 12736228)
1. Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patients.
Nowrousian MR; Waschke S; Bojko P; Welt A; Schuett P; Ebeling P; Flasshove M; Moritz T; Schuette J; Seeber S
Ann Oncol; 2003; 14 Suppl 1():i29-36. PubMed ID: 12736228
[TBL] [Abstract][Full Text] [Related]
2. [Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF].
Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou SY; Zhou AP; Zhang CG; Ai B
Ai Zheng; 2003 Dec; 22(12):1311-6. PubMed ID: 14693058
[TBL] [Abstract][Full Text] [Related]
3. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF.
Demirer T; Ayli M; Ozcan M; Gunel N; Haznedar R; Dagli M; Fen T; Genc Y; Dincer S; Arslan O; Gürman G; Demirer S; Ozet G; Uysal A; Konuk N; Ilhan O; Koc H; Akan H
Br J Haematol; 2002 Feb; 116(2):468-74. PubMed ID: 11841454
[TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
5. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.
Koç ON; Gerson SL; Cooper BW; Laughlin M; Meyerson H; Kutteh L; Fox RM; Szekely EM; Tainer N; Lazarus HM
J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622
[TBL] [Abstract][Full Text] [Related]
6. Correlation between granulocyte/macrophage-colony-forming units and CD34+ cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize peripheral blood progenitor cells.
Vogel W; Kunert C; Blumenstengel K; Fricke HJ; Kath R; Sayer HG; Höffken K
J Cancer Res Clin Oncol; 1998; 124(6):341-5. PubMed ID: 9692843
[TBL] [Abstract][Full Text] [Related]
7. Mobilization of peripheral blood stem cells with paclitaxel and rhG-CSF in high-risk breast cancer patients.
Meehan KR; Slack R; Gehan E; Herscowitz HB; Areman EM; Ebadi M; Cairo MS; Lippman ME
J Hematother Stem Cell Res; 2002 Apr; 11(2):415-21. PubMed ID: 11983113
[TBL] [Abstract][Full Text] [Related]
8. Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide.
McQuaker IG; Haynes AP; Stainer C; Anderson S; Russell NH
Br J Haematol; 1997 Jul; 98(1):228-33. PubMed ID: 9233591
[TBL] [Abstract][Full Text] [Related]
9. Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin.
Brugger W; Bross K; Frisch J; Dern P; Weber B; Mertelsmann R; Kanz L
Blood; 1992 Mar; 79(5):1193-200. PubMed ID: 1371415
[TBL] [Abstract][Full Text] [Related]
10. Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers.
Carlo-Stella C; Di Nicola M; Milani R; Guidetti A; Magni M; Milanesi M; Longoni P; Matteucci P; Formelli F; Ravagnani F; Corradini P; Gianni AM
Blood; 2004 May; 103(9):3287-95. PubMed ID: 14726397
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
Aurlien E; Holte H; Kvaløy S; Jakobsen E; Rusten LS; Kvalheim G
Eur J Haematol Suppl; 2001 Jul; 64():14-20. PubMed ID: 11486395
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of two doses of cyclophosphamide with etoposide and G-CSF for mobilization of peripheral blood stem cells in 318 patients with stage II-III breast cancer.
Schwartzberg LS; Weaver CH; Birch R; Manner C; Tauer K; Beeker T; Morgan-Ihrig C; MacAneny B; Leff R; Smith R; Hainsworth J; Greco T; Schwerkoske J; Murphy MN; Buckner CD
J Hematother; 1998 Apr; 7(2):141-50. PubMed ID: 9597571
[TBL] [Abstract][Full Text] [Related]
14. Feasibility study of IL-11 and granulocyte colony-stimulating factor after myelosuppressive chemotherapy to mobilize peripheral blood stem cells from heavily pretreated patients.
Goldman SC; Bracho F; Davenport V; Slack R; Areman E; Shen V; Lenarsky C; Weinthal J; Hughes R; Cairo MS
J Pediatr Hematol Oncol; 2001; 23(5):300-5. PubMed ID: 11464987
[TBL] [Abstract][Full Text] [Related]
15. Mobilization of peripheral blood progenitor cells in patients with breast cancer: a prospective randomized trial comparing rhG-CSF with the combination of rhG-CSF plus rhEpo after VIP-E chemotherapy.
Waller CF; von Lintig F; Daskalakis A; Musahl V; Lange W
Bone Marrow Transplant; 1999 Jul; 24(1):19-24. PubMed ID: 10435729
[TBL] [Abstract][Full Text] [Related]
16. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor.
Schwartzberg LS; Birch R; Hazelton B; Tauer KW; Lee P; Altemose R; George C; Blanco R; Wittlin F; Cohen J
J Hematother; 1992; 1(4):317-27. PubMed ID: 1285381
[TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
Aurlien E; Holte H; Pharo A; Kvaløy S; Jakobsen E; Smeland EB; Kvalheim G
Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778
[TBL] [Abstract][Full Text] [Related]
18. Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R-ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation.
Xia W; Ma CK; Reid C; Bai L; Wong K; Kerridge I; Ward C; Greenwood M
J Clin Apher; 2014 Dec; 29(6):322-30. PubMed ID: 24944079
[TBL] [Abstract][Full Text] [Related]
19. Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotheraupetic agent, associated with rhG-CSF.
Gómez-Espuch J; Moraleda JM; Ortuño F; Lozano ML; Ayala F; Vallejo C; de Arriba F; Vicente V
Bone Marrow Transplant; 2000 Feb; 25(3):231-5. PubMed ID: 10673692
[TBL] [Abstract][Full Text] [Related]
20. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens.
Stewart DA; Guo D; Morris D; Poon MC; Ruether BA; Jones AR; Klassen J; Auer I; Luider J; Chaudhry A; Brown C; Russell JA
Bone Marrow Transplant; 1999 Jan; 23(2):111-7. PubMed ID: 10197794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
